News
Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...
The firm will evaluate VS-7375 as both monotherapy and in combination with Eli Lilly's EGFR inhibitor Erbitux in the study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback